Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?
G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), F. Cognetti(Sapienza University of Rome), E. Terzoli(Catholic University of America), Emilio Bria(Università Cattolica del Sacro Cuore), Alessandra Felici, Alessandra Fabi(Agostino Gemelli University Polyclinic), Carmen Nuzzo, Federica Cuppone(Italian Medicines Agency), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Mariangela Ciccarese, Mario Mandalà(University of Perugia), Fabiana Letizia Cecere(Cancer Institute (WIA)), Paolo Carlini(National Cancer Institute)
Cited by 41
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k